Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension

M. A. Munger, W. F. Rutherford, L. Anderson, A. I. Hakki, F. M. Gonzalez, E. M. Bednarczyk, G. Emmanuel, S. G. Weed, Edward A Panacek, J. A. Green

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

To evaluate the acute BP response to iv fenoldopam mesylate (FNP), 14 patients with severe hypertension (diastolic BP 120 to 170 mm Hg) were studied in an open-label trial. Initial infusion rate of FNP was 0.1 μg/kg·min. Titration to diastolic BP goal (95 to 110 mm Hg) was followed by a constant infusion phase (≥ 6 h), a detitration phase (2 h), and a postinfusion phase. FNP reduced BP by 27/29 mm Hg (p < .001) with no sigificant effect on heart rate. Maintenance of the BP effect was noted through the 6 h of constant rate infusion. Mild, transient vasodilating-associated adverse effects were noted with FNP. We conclude that FNP is an effective, well-tolerated iv antihypertensive agent for acute BP reduction in a severely hypertensive population.

Original languageEnglish (US)
Pages (from-to)502-504
Number of pages3
JournalCritical Care Medicine
Volume18
Issue number5
StatePublished - 1990
Externally publishedYes

Fingerprint

Fenoldopam
Hypertension
Antihypertensive Agents
Heart Rate
Maintenance
Population

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Munger, M. A., Rutherford, W. F., Anderson, L., Hakki, A. I., Gonzalez, F. M., Bednarczyk, E. M., ... Green, J. A. (1990). Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension. Critical Care Medicine, 18(5), 502-504.

Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension. / Munger, M. A.; Rutherford, W. F.; Anderson, L.; Hakki, A. I.; Gonzalez, F. M.; Bednarczyk, E. M.; Emmanuel, G.; Weed, S. G.; Panacek, Edward A; Green, J. A.

In: Critical Care Medicine, Vol. 18, No. 5, 1990, p. 502-504.

Research output: Contribution to journalArticle

Munger, MA, Rutherford, WF, Anderson, L, Hakki, AI, Gonzalez, FM, Bednarczyk, EM, Emmanuel, G, Weed, SG, Panacek, EA & Green, JA 1990, 'Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension', Critical Care Medicine, vol. 18, no. 5, pp. 502-504.
Munger MA, Rutherford WF, Anderson L, Hakki AI, Gonzalez FM, Bednarczyk EM et al. Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension. Critical Care Medicine. 1990;18(5):502-504.
Munger, M. A. ; Rutherford, W. F. ; Anderson, L. ; Hakki, A. I. ; Gonzalez, F. M. ; Bednarczyk, E. M. ; Emmanuel, G. ; Weed, S. G. ; Panacek, Edward A ; Green, J. A. / Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension. In: Critical Care Medicine. 1990 ; Vol. 18, No. 5. pp. 502-504.
@article{8ae0371a50204a4db88a2f654f424c42,
title = "Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension",
abstract = "To evaluate the acute BP response to iv fenoldopam mesylate (FNP), 14 patients with severe hypertension (diastolic BP 120 to 170 mm Hg) were studied in an open-label trial. Initial infusion rate of FNP was 0.1 μg/kg·min. Titration to diastolic BP goal (95 to 110 mm Hg) was followed by a constant infusion phase (≥ 6 h), a detitration phase (2 h), and a postinfusion phase. FNP reduced BP by 27/29 mm Hg (p < .001) with no sigificant effect on heart rate. Maintenance of the BP effect was noted through the 6 h of constant rate infusion. Mild, transient vasodilating-associated adverse effects were noted with FNP. We conclude that FNP is an effective, well-tolerated iv antihypertensive agent for acute BP reduction in a severely hypertensive population.",
author = "Munger, {M. A.} and Rutherford, {W. F.} and L. Anderson and Hakki, {A. I.} and Gonzalez, {F. M.} and Bednarczyk, {E. M.} and G. Emmanuel and Weed, {S. G.} and Panacek, {Edward A} and Green, {J. A.}",
year = "1990",
language = "English (US)",
volume = "18",
pages = "502--504",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension

AU - Munger, M. A.

AU - Rutherford, W. F.

AU - Anderson, L.

AU - Hakki, A. I.

AU - Gonzalez, F. M.

AU - Bednarczyk, E. M.

AU - Emmanuel, G.

AU - Weed, S. G.

AU - Panacek, Edward A

AU - Green, J. A.

PY - 1990

Y1 - 1990

N2 - To evaluate the acute BP response to iv fenoldopam mesylate (FNP), 14 patients with severe hypertension (diastolic BP 120 to 170 mm Hg) were studied in an open-label trial. Initial infusion rate of FNP was 0.1 μg/kg·min. Titration to diastolic BP goal (95 to 110 mm Hg) was followed by a constant infusion phase (≥ 6 h), a detitration phase (2 h), and a postinfusion phase. FNP reduced BP by 27/29 mm Hg (p < .001) with no sigificant effect on heart rate. Maintenance of the BP effect was noted through the 6 h of constant rate infusion. Mild, transient vasodilating-associated adverse effects were noted with FNP. We conclude that FNP is an effective, well-tolerated iv antihypertensive agent for acute BP reduction in a severely hypertensive population.

AB - To evaluate the acute BP response to iv fenoldopam mesylate (FNP), 14 patients with severe hypertension (diastolic BP 120 to 170 mm Hg) were studied in an open-label trial. Initial infusion rate of FNP was 0.1 μg/kg·min. Titration to diastolic BP goal (95 to 110 mm Hg) was followed by a constant infusion phase (≥ 6 h), a detitration phase (2 h), and a postinfusion phase. FNP reduced BP by 27/29 mm Hg (p < .001) with no sigificant effect on heart rate. Maintenance of the BP effect was noted through the 6 h of constant rate infusion. Mild, transient vasodilating-associated adverse effects were noted with FNP. We conclude that FNP is an effective, well-tolerated iv antihypertensive agent for acute BP reduction in a severely hypertensive population.

UR - http://www.scopus.com/inward/record.url?scp=0025290528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025290528&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 502

EP - 504

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 5

ER -